Lazard Asset Management
IRON icon

Lazard Asset Management’s Disc Medicine IRON Stock Holding History

Lazard Asset Management’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.56M Sell
35,034
-4,366
-11% -$300K ﹤0.01% 870
2026
Q1 		$2.52M Sell
39,400
-18,653
-32% -$1.29M ﹤0.01% 798
2025
Q4 		$4.61M Buy
+58,053
New +$4.91M 0.01% 573

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Lazard Asset Management's IRON Position: Q2 2026 in Review

Lazard Asset Management reduced its Disc Medicine (IRON) stake by 11% in Q2 2026, selling an estimated $300K and leaving 35,034 shares worth $2.56M. The position accounts for ﹤0.01% of the portfolio, ranked #870.

Lazard Asset Management first reported a position in IRON in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.61M in Q4 2025. 216 funds tracked by Wall St. Rank hold IRON as of Q2 2026.

  • Lazard Asset Management held 35,034 shares of Disc Medicine worth $2.56M as of Q2 2026.
  • Lazard Asset Management sold 4,366 Disc Medicine shares in Q2 2026, an estimated $300K.
  • Disc Medicine made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #870 holding.
  • Lazard Asset Management first reported a position in Disc Medicine in Q4 2025 and has held it in 3 quarters since.
  • Lazard Asset Management's Disc Medicine position peaked at $4.61M in Q4 2025.
  • 216 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.